Ambros Therapeutics

RA Capital Management-backed biotech developing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1); announced an all-stock merger with Nasdaq-listed Werewolf Therapeutics and a concurrent oversubscribed $150 million private placement in 2026, with the combined company to trade as AMBX.